Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids

Paolo A. Cortesi, Luciana Scalone, Andrea Belisari, Domenico Bonamonte, Serafinella Patrizia Cannavò, Antonio Cristaudo, Ornella De Pità, Rosella Gallo, Alberto Giannetti, Massimo Gola, Paolo D. Pigatto, Lorenzo G. Mantovani

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background Little is known about the socio-economic burden of severe chronic hand eczema in patients refractory to treatment with potent corticosteroids. Objectives To estimate the socio-economic burden of severe chronic hand eczema refractory to potent topical corticosteroids, and to establish an algorithm for the estimation of the health-related quality of life EuroQol five-dimensional (EQ-5D) utility index from the Dermatology Life Quality Index (DLQI) summary score. Methods A multicentre cost of illness study was conducted, adopting the societal perspective. Adult patients with severe and refractory chronic hand eczema were enrolled. Direct (e.g. drug treatment and travel) and indirect (i.e. loss of productivity) mean costs/patient-month were estimated. Health-related quality of life was assessed with the EQ-5D and DLQI questionnaires. An ordinary least square regression model was used to investigate relationships between health-related quality of life scores. Results One hundred and four valid patients (mean age 44.5 years, 39.4% male) participated. Overall mean costs were €418.3/patient-month: loss of productivity contributed 43.7%, followed by hospitalization (16.1%) and travel (10.3%). Health-related quality of life scores were, on average, 0.50 (EQ-5D utility) and 11.3 (DLQI). Utility and DLQI summary were significantly related to each other. Conclusions Wellbeing and loss of productivity are the most important consequences in these patients. Appropriate treatment is necessary to improve patient health and productivity, which will contribute to reducing societal costs.

Original languageEnglish
Pages (from-to)158-168
Number of pages11
JournalContact Dermatitis
Volume70
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Eczema
Adrenal Cortex Hormones
Hand
Quality of Life
Costs and Cost Analysis
Dermatology
Therapeutics
Economics
Cost of Illness
Least-Squares Analysis
Hospitalization
Health
Pharmaceutical Preparations

Keywords

  • chronic hand eczema
  • cost of illness
  • health-related quality of life
  • healthcare costs
  • loss of productivity
  • refractoriness to therapy

ASJC Scopus subject areas

  • Dermatology
  • Immunology and Allergy

Cite this

Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. / Cortesi, Paolo A.; Scalone, Luciana; Belisari, Andrea; Bonamonte, Domenico; Cannavò, Serafinella Patrizia; Cristaudo, Antonio; De Pità, Ornella; Gallo, Rosella; Giannetti, Alberto; Gola, Massimo; Pigatto, Paolo D.; Mantovani, Lorenzo G.

In: Contact Dermatitis, Vol. 70, No. 3, 03.2014, p. 158-168.

Research output: Contribution to journalArticle

Cortesi, PA, Scalone, L, Belisari, A, Bonamonte, D, Cannavò, SP, Cristaudo, A, De Pità, O, Gallo, R, Giannetti, A, Gola, M, Pigatto, PD & Mantovani, LG 2014, 'Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids', Contact Dermatitis, vol. 70, no. 3, pp. 158-168. https://doi.org/10.1111/cod.12130
Cortesi, Paolo A. ; Scalone, Luciana ; Belisari, Andrea ; Bonamonte, Domenico ; Cannavò, Serafinella Patrizia ; Cristaudo, Antonio ; De Pità, Ornella ; Gallo, Rosella ; Giannetti, Alberto ; Gola, Massimo ; Pigatto, Paolo D. ; Mantovani, Lorenzo G. / Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. In: Contact Dermatitis. 2014 ; Vol. 70, No. 3. pp. 158-168.
@article{220eba8fbd8b49829fdc4a3903f1b73d,
title = "Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids",
abstract = "Background Little is known about the socio-economic burden of severe chronic hand eczema in patients refractory to treatment with potent corticosteroids. Objectives To estimate the socio-economic burden of severe chronic hand eczema refractory to potent topical corticosteroids, and to establish an algorithm for the estimation of the health-related quality of life EuroQol five-dimensional (EQ-5D) utility index from the Dermatology Life Quality Index (DLQI) summary score. Methods A multicentre cost of illness study was conducted, adopting the societal perspective. Adult patients with severe and refractory chronic hand eczema were enrolled. Direct (e.g. drug treatment and travel) and indirect (i.e. loss of productivity) mean costs/patient-month were estimated. Health-related quality of life was assessed with the EQ-5D and DLQI questionnaires. An ordinary least square regression model was used to investigate relationships between health-related quality of life scores. Results One hundred and four valid patients (mean age 44.5 years, 39.4{\%} male) participated. Overall mean costs were €418.3/patient-month: loss of productivity contributed 43.7{\%}, followed by hospitalization (16.1{\%}) and travel (10.3{\%}). Health-related quality of life scores were, on average, 0.50 (EQ-5D utility) and 11.3 (DLQI). Utility and DLQI summary were significantly related to each other. Conclusions Wellbeing and loss of productivity are the most important consequences in these patients. Appropriate treatment is necessary to improve patient health and productivity, which will contribute to reducing societal costs.",
keywords = "chronic hand eczema, cost of illness, health-related quality of life, healthcare costs, loss of productivity, refractoriness to therapy",
author = "Cortesi, {Paolo A.} and Luciana Scalone and Andrea Belisari and Domenico Bonamonte and Cannav{\`o}, {Serafinella Patrizia} and Antonio Cristaudo and {De Pit{\`a}}, Ornella and Rosella Gallo and Alberto Giannetti and Massimo Gola and Pigatto, {Paolo D.} and Mantovani, {Lorenzo G.}",
year = "2014",
month = "3",
doi = "10.1111/cod.12130",
language = "English",
volume = "70",
pages = "158--168",
journal = "Contact Dermatitis",
issn = "0105-1873",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids

AU - Cortesi, Paolo A.

AU - Scalone, Luciana

AU - Belisari, Andrea

AU - Bonamonte, Domenico

AU - Cannavò, Serafinella Patrizia

AU - Cristaudo, Antonio

AU - De Pità, Ornella

AU - Gallo, Rosella

AU - Giannetti, Alberto

AU - Gola, Massimo

AU - Pigatto, Paolo D.

AU - Mantovani, Lorenzo G.

PY - 2014/3

Y1 - 2014/3

N2 - Background Little is known about the socio-economic burden of severe chronic hand eczema in patients refractory to treatment with potent corticosteroids. Objectives To estimate the socio-economic burden of severe chronic hand eczema refractory to potent topical corticosteroids, and to establish an algorithm for the estimation of the health-related quality of life EuroQol five-dimensional (EQ-5D) utility index from the Dermatology Life Quality Index (DLQI) summary score. Methods A multicentre cost of illness study was conducted, adopting the societal perspective. Adult patients with severe and refractory chronic hand eczema were enrolled. Direct (e.g. drug treatment and travel) and indirect (i.e. loss of productivity) mean costs/patient-month were estimated. Health-related quality of life was assessed with the EQ-5D and DLQI questionnaires. An ordinary least square regression model was used to investigate relationships between health-related quality of life scores. Results One hundred and four valid patients (mean age 44.5 years, 39.4% male) participated. Overall mean costs were €418.3/patient-month: loss of productivity contributed 43.7%, followed by hospitalization (16.1%) and travel (10.3%). Health-related quality of life scores were, on average, 0.50 (EQ-5D utility) and 11.3 (DLQI). Utility and DLQI summary were significantly related to each other. Conclusions Wellbeing and loss of productivity are the most important consequences in these patients. Appropriate treatment is necessary to improve patient health and productivity, which will contribute to reducing societal costs.

AB - Background Little is known about the socio-economic burden of severe chronic hand eczema in patients refractory to treatment with potent corticosteroids. Objectives To estimate the socio-economic burden of severe chronic hand eczema refractory to potent topical corticosteroids, and to establish an algorithm for the estimation of the health-related quality of life EuroQol five-dimensional (EQ-5D) utility index from the Dermatology Life Quality Index (DLQI) summary score. Methods A multicentre cost of illness study was conducted, adopting the societal perspective. Adult patients with severe and refractory chronic hand eczema were enrolled. Direct (e.g. drug treatment and travel) and indirect (i.e. loss of productivity) mean costs/patient-month were estimated. Health-related quality of life was assessed with the EQ-5D and DLQI questionnaires. An ordinary least square regression model was used to investigate relationships between health-related quality of life scores. Results One hundred and four valid patients (mean age 44.5 years, 39.4% male) participated. Overall mean costs were €418.3/patient-month: loss of productivity contributed 43.7%, followed by hospitalization (16.1%) and travel (10.3%). Health-related quality of life scores were, on average, 0.50 (EQ-5D utility) and 11.3 (DLQI). Utility and DLQI summary were significantly related to each other. Conclusions Wellbeing and loss of productivity are the most important consequences in these patients. Appropriate treatment is necessary to improve patient health and productivity, which will contribute to reducing societal costs.

KW - chronic hand eczema

KW - cost of illness

KW - health-related quality of life

KW - healthcare costs

KW - loss of productivity

KW - refractoriness to therapy

UR - http://www.scopus.com/inward/record.url?scp=84896735976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896735976&partnerID=8YFLogxK

U2 - 10.1111/cod.12130

DO - 10.1111/cod.12130

M3 - Article

VL - 70

SP - 158

EP - 168

JO - Contact Dermatitis

JF - Contact Dermatitis

SN - 0105-1873

IS - 3

ER -